Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
McKinsey
Merck
Moodys
Dow

Last Updated: September 30, 2022

Details for Patent: 10,052,314


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 10,052,314 protect, and when does it expire?

Patent 10,052,314 protects ERLEADA and is included in one NDA.

This patent has sixty-two patent family members in thirty-two countries.

Summary for Patent: 10,052,314
Title:Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
Inventor(s): Chen; Isan (San Diego, CA)
Assignee: Aragon Pharmaceuticals, Inc. (San Diego, CA)
Application Number:15/851,444
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,052,314
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 10,052,314

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-001 Feb 14, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC) See Plans and Pricing
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-001 Feb 14, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC) See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,052,314

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013323861 See Plans and Pricing
Australia 2018206695 See Plans and Pricing
Australia 2020244431 See Plans and Pricing
Brazil 112015006705 See Plans and Pricing
Canada 2885415 See Plans and Pricing
Chile 2015000715 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Mallinckrodt
Dow
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.